Cargando…

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

The use of the glycoprotein (GP) IIb/IIIa receptor antagonist Abciximab has over the years become an important part of the anticoagulant regimen in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Abciximab is a potent inhibitor of platelet aggregation and thrombu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iversen, Allan, Galatius, Søren, Jensen, Jan S
Formato:	Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers Ltd 2008
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801861/ https://www.ncbi.nlm.nih.gov/pubmed/20066137 http://dx.doi.org/10.2174/157340308786349480

Ejemplares similares

Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis
por: Hahn, JongSung, et al.
Publicado: (2023)

Intracoronary versus Intravenous Administration of Abciximab in Patients with Acute Coronary Syndrome: A Meta-Analysis
por: Wang, Jie-Ning, et al.
Publicado: (2013)

Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis
por: Niu, Xiao-Wei, et al.
Publicado: (2017)

Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
por: Sim, Doo Sun, et al.
Publicado: (2003)

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction
por: Namazi, Mohammad Hasan, et al.
Publicado: (2013)

Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials
por: Sun, Binjie, et al.
Publicado: (2017)

Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
por: Iannetta, Loredana, et al.
Publicado: (2013)

Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases
por: Abdeladim, Salma, et al.
Publicado: (2021)

The Long-term Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro(®)) Coated Stent in Patients with Coronary Artery Disease
por: Kim, Weon, et al.
Publicado: (2004)

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction
por: Choi, Woong Gil, et al.
Publicado: (2011)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Absence of platelet membrane glycoproteins IIb/IIIa from monocytes
Publicado: (1985)

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
por: Kaluski, Edo
Publicado: (2008)

Influence of glycoprotein IIb/IIIa inhibitors on bleeding events after successful resuscitation and percutaneous coronary intervention
por: Biever, Paul Marc, et al.
Publicado: (2019)

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome
por: Shakoor, Muhammad Tariq, et al.
Publicado: (2014)

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
por: Suwaidi, Jassim Al, et al.
Publicado: (2001)

The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma
por: Kim, Seo-Hee, et al.
Publicado: (2021)

Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-naïve patients undergoing elective percutaneous coronary intervention
por: Habibi, Zarina, et al.
Publicado: (2023)

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
por: Gu, Youlan L, et al.
Publicado: (2009)

Effects of intracoronary antithrombotics on ventricular function: A comparison of tenecteplase versus abciximab during primary percutaneous intervention in myocardial infarction
por: Morales-Ponce, Francisco J., et al.
Publicado: (2021)

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction
por: Howard, J. P., et al.
Publicado: (2014)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

Effect of Platelet Glycoprotein IIb/IIIa PLA2 Polymorphism on Severity of Pulmonary Thromboembolism
por: Boroujeni, Hamid Rouhi, et al.
Publicado: (2014)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors
por: Hekmat, Hamidreza, et al.
Publicado: (2022)

P2Y(12) Receptor Blockade Augments Glycoprotein IIb‐IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity
por: Berny‐Lang, Michelle A., et al.
Publicado: (2013)

Intracoronary Glycoprotein IIb/IIIa Inhibitors Improve Short-Term Mortality and Reinfarction in East Asian Patients with ST-Segment Elevation Myocardial Infarction after Thrombus Aspiration: A Meta-Analysis
por: Wu, Jia-hong, et al.
Publicado: (2018)

Tirofiban, a Glycoprotein IIb/IIIa Antagonist, Has a Protective Effect on Decompression Sickness in Rats: Is the Crosstalk Between Platelet and Leukocytes Essential?
por: Lambrechts, Kate, et al.
Publicado: (2018)

Role of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet proteins
Publicado: (1990)

Thrombin-induced platelet membrane glycoprotein IIb and IIIa complex formation. An electron microscope study
Publicado: (1981)

Glycoprotein IIb/IIIa and P2Y(12) Induction by Oligochitosan Accelerates Platelet Aggregation
por: Periayah, Mercy Halleluyah, et al.
Publicado: (2014)

Abciximab: Abciximab-induced alveolar haemorrhage: case report
Publicado: (2021)

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
por: Vergara-Jimenez, Jennifer, et al.
Publicado: (2010)

Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both?
por: Silva, Matthew A, et al.
Publicado: (2006)

A prospective analysis of complications related to the use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
por: Rocha, RM, et al.
Publicado: (2001)

Relationship of Platelet Glycoprotein IIb/IIIa and CD62P With Hypercoagulable State After Oncologic Surgery
por: Zhong, Xin, et al.
Publicado: (2020)

Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
por: Xu, Haiyan, et al.
Publicado: (2017)

Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis
por: De Luca, G, et al.
Publicado: (2008)

Evidence that activation of platelet calpain is induced as a consequence of binding of adhesive ligand to the integrin, glycoprotein IIb-IIIa
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_h7qutr7bi162scsfr9trd0835h